Understanding Inflammatory Bowel Disease in Seoul, Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the incidence, prevalence, clinical characteristics, and prognosis of Crohn's disease and ulcerative colitis in the Songpa-Kangdong district of Seoul, Korea, over a 30-year period from 1986 to 2017. The research will analyze long-term trends in the epidemiology of these inflammatory bowel diseases, which are characterized by chronic inflammation of the gut. The study will also investigate the clinical features at diagnosis and the evolution of the diseases over time, providing valuable insights into their impact in the region.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Definite cases of CD and UC

Patients are diagnosed with CD if they meet at least 2 of the following criteria:

1. clinical history of abdominal pain, weight loss, malaise, diarrhea, and/or rectal bleeding
2. endoscopic findings of mucosal cobblestoning, linear ulceration, skip areas, or perianal disease
3. radiologic findings of stricture, fistula, mucosal cobblestoning, or ulceration
4. macroscopic appearance of bowel wall induration, mesenteric lymphadenopathy, and "creeping fat" at laparotomy
5. pathologic findings of transmural inflammation and/or epithelioid granulomas

Only patients who meet these criteria for at least 2 months are included.

Patients are diagnosed with UC only if all 3 of the following criteria are present

1. a typical history of diarrhea or blood and pus or both in the stool for longer than 4 weeks
2. a typical sigmoidoscopic or colonoscopic picture with diffusely granular, friable, or ulcerated mucosa without rectal sparing or skip lesions or radiological signs of characteristic continuous granular or ulcerated mucosa
3. characteristic histopathological signs of inflammation on biopsy

Exclusion Criteria:

* IBD unclassified
* Ethnic groups other than Korean

Where it's running

• Asan Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Suk-Kyun Yang, M.D. — Asan Medical Center
• Study coordinator: Suk-Kyun Yang, M.D.
• Email: sky@amc.seoul.kr
• Phone: +82-2-3010-3901

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

• Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease

  This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619547

• Pregnancy in people with inflammatory bowel disease

  This project will see if pregnancy changes how often women with IBD have disease flares by analyzing registry data from women who had pregnancies.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07377188

• Evaluating Upadacitinib for Inflammatory Bowel Disease

  This study is testing how well the oral medication Upadacitinib works for people in China with Inflammatory Bowel Disease who haven't responded to other treatments.

  Recruiting at 6 sites Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT06780683

• Continued TAK-279 treatment in adults with ulcerative colitis or Crohn's disease

  Adults with moderate to severe ulcerative colitis or Crohn's disease who responded to earlier TAK-279 can continue TAK-279 for up to two years to see if it remains safe and lowers bowel inflammation and symptoms.

  Recruiting at 16 sites Phase 2 Takeda · Glen Burnie, Maryland and 15 other locations · NCT06764615

• Treatment of Ulcerative Colitis and Crohn's Disease with Vedolizumab

  This study is testing if a new medication called Vedolizumab can help adults with Ulcerative Colitis or Crohn's Disease feel better and stay symptom-free over a year.

  Recruiting at 78 sites Phase 4 Takeda · Birmingham, Alabama and 100 other locations · NCT06581328

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.